Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

DelveInsight's Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

The portfolio strategy team at Goldman Sachs ranks the 11 sectors in the S&P 500 index by absolute and relative price/earnings ratios.

Midsize U.S. metros are driving job growth, attracting talent, reshaping local economies, and offering a vibrant social scene ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...